Want to join the conversation?
In 2Q16, $GEVO's R&D expense was $1.5MM versus $1.8MM in 2Q15, hurt by a reduction in employee related expense. SG&A dipped to $2.1MM in the quarter, mainly due to decrease in litigation legal expenses. Non-cash stock-based compensation was about $0.2MM in 2Q16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?